Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141081 | 0.89 | OPRM1 (0.47) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL25663554 | 0.83 | OPRM1 (0.42) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL17700363 | 0.78 | ALDH1A1 (0.45) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL4974601 | 0.77 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL11795941 | 0.77 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL11673147 | 0.75 | HDAC3 (0.62) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL9356091 | 0.74 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL140525 | 0.74 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL12493194 | 0.73 | HTT (0.42) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL11530675 | 0.72 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | HDAC3 299/4885HDAC1 431/4885HDAC2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.